Qiagen N.V. (QGEN)
NYSE: QGEN · Real-Time Price · USD
42.96
+1.10 (2.63%)
At close: May 12, 2025, 4:00 PM
42.96
0.00 (0.00%)
After-hours: May 12, 2025, 7:00 PM EDT
Qiagen Revenue
Qiagen had revenue of $483.46M in the quarter ending March 31, 2025, with 5.37% growth. This brings the company's revenue in the last twelve months to $2.00B, up 3.31% year-over-year. In the year 2024, Qiagen had annual revenue of $1.98B with 0.66% growth.
Revenue (ttm)
$2.00B
Revenue Growth
+3.31%
P/S Ratio
4.64
Revenue / Employee
$335,658
Employees
5,967
Market Cap
9.30B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.98B | 12.90M | 0.66% |
Dec 31, 2023 | 1.97B | -176.21M | -8.23% |
Dec 31, 2022 | 2.14B | -110.14M | -4.89% |
Dec 31, 2021 | 2.25B | 381.31M | 20.39% |
Dec 31, 2020 | 1.87B | 343.92M | 22.53% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
QGEN News
- 7 hours ago - QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software - Business Wire
- 4 days ago - Qiagen N.V. (QGEN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - QIAGEN announces plans for transition in leadership of Supervisory Board - Business Wire
- 5 days ago - QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase - Business Wire
- 5 days ago - QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting - Business Wire
- 9 days ago - Activist Fivespan has a stake in Qiagen. Here are 3 levers to boost the company's growth and improve value - CNBC
- 13 days ago - QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control - Business Wire
- 20 days ago - QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025 - Business Wire